New data show abbott's heartmate 3™ heart pump extends life beyond five years for advanced heart failure patients

New data from the momentum 3 study showed for the first time that a heart pump can extend survival to five years and beyond for advanced heart failure patients prior data1 have shown survival for advanced heart failure patients who don't receive either a heart pump or heart transplant is less than one year the momentum 3 study showcases the significant survival benefits of abbott's heart pump technology, particularly in a patient population with limited therapy options abbott park, ill., aug. 29, 2022 /prnewswire/ -- abbott (nyse: abt) today announced new late-breaking data that show its heartmate 3™ heart pump extends survival of advanced heart failure patients by at least five years, providing a clear life-saving option for people battling later stage disease.
ABT Ratings Summary
ABT Quant Ranking